How to Start a Medicap Pharmacy Franchise in 7 Steps: Checklist

The current official Medicap Pharmacy franchise page describes opportunities to open a new pharmacy, acquire an existing operation, or use a co-brand offering. Contractual opening requirements below follow the 2025 FDD and attached agreements where the marketing page is broader.

The 2025 FDD does not disclose a universal minimum net worth, liquid-capital threshold, minimum credit score, pharmacy-ownership experience requirement, or education requirement for every new applicant. Meeting any informal screening standard therefore should not be treated as approval. The FDD does disclose stricter qualification language for a buyer taking over an existing Medicap franchise: the proposed transferee must be acceptable to Medicap as to character and reputation, credit rating, financial capability, and competent business qualifications.

Operational eligibility is different from applicant approval. The franchisee must keep a valid pharmacy business license, maintain required state and federal licenses for controlled substances and related regulated items, and ensure the pharmacy is always supervised by a licensed pharmacist. The owner is not required by Item 15 to work personally in the pharmacy every day, but the franchisee remains responsible for the business, employees, and compliance.

Sources: 2025 FDD, Item 1 p. 1; Item 15 p. 35; Item 17 pp. 36–39; Franchise Agreement §§II.A and VIII.A.

The evidence supports eight major stages. The order below follows contractual dependencies rather than FDD Item numbering; steps involving landlords, regulators, lenders, contractors, insurers, suppliers, and network onboarding can overlap, but each can still delay opening.

Sources: 2025 FDD, Items 8–12 and 15–17; Franchise Agreement §§I, II, V, VI.B(13), X and XIV; FTC Consumer’s Guide to Buying a Franchise.

A buyer should not merge these paths. The FDD gives different opening windows for a start-up and a conversion, while a transfer of an existing Medicap franchise adds transferee approval conditions. The Co-Brand Addendum permits approved additional marks but does not replace the Medicap Pharmacy primary mark and is not an area-development agreement.

Sources: 2025 FDD, Items 7, 11, 12 and 17; Franchise Agreement §VIII; Co-Brand Addendum. The Cardinal Health co-brand announcement provides historical public context, but the current FDD and addendum control the contractual path.

The franchisee is contractually responsible for selecting the site, and the Franchise Agreement prohibits acquiring a particular site before Medicap approval. Medicap considers the space, trade-area demographics and density, nearby competition, customer access, and proximity to other Medicap businesses. Approval is not an endorsement of site viability.

The 2025 FDD grants a right to operate at one approved location but no exclusive territory, no option or right of first refusal for additional franchises, and no protected customer base. Relocation requires Medicap consent, which the FDD says may be withheld in its sole discretion.

Sources: 2025 FDD, Item 11 pp. 26–27; Item 12 pp. 32–33; Franchise Agreement §I.A and §V.A.

Three day-based periods are directly comparable as lengths, although they begin from different triggers and must not be added into a single opening estimate. The federal review period controls the pre-signing stage; the site figure is a stated general response pattern, not a deadline; the 90-day period is a contractual outside limit for an existing-business opening.

The broader official opening windows remain format-specific: 2 weeks to 3 months for a conversion and 6 to 12 months for a new business, both measured from signing to opening. Item 11 expressly identifies site selection, lease negotiation, financing, permits or zoning variances, construction, and equipment, fixture, or sign installation as factors that can extend the new-store process.

The FTC describes the pre-sale disclosure rule in its Franchise Fundamentals FDD guidance. The rule uses calendar days, not business days.

The franchisee controls most execution work; Medicap controls specific approvals and system requirements; third parties control several regulated and real-estate dependencies. This division matters because the FDD’s typical opening range is not a promise that landlords, regulators, lenders, contractors, insurers, suppliers, or network administrators will finish on a particular date.

Federal controlled-substance requirements should be verified directly with the U.S. Drug Enforcement Administration’s Controlled Substances Act resources and the applicable state licensing authorities. Exhibit B also makes current pharmacy-profile information relevant to network onboarding; NCPDP Online is the official profile portal referenced by that onboarding process.

The 2025 FDD states that Medicap does not provide an initial training program to the franchisee. It therefore discloses no standard franchisor training duration, required owner attendees, test, retake rule, or franchisor certification that automatically authorizes opening. The franchisee is responsible for recruiting, hiring, and training its employees.

That does not eliminate regulated training. Item 1 identifies Fraud, Waste and Abuse training requirements and Item 11 says Medicap may assist franchisees in obtaining web-based HIPAA, Fraud, Waste and Abuse, or similar training and provides access to a compliance learning solution. Any additional training tied to a chosen PMS, POS, Retail Solution, immunization service, point-of-care testing program, or other regulated service is separate from a base franchisor initial-training course.

Sources: 2025 FDD, Item 1 pp. 3–5; Item 11 pp. 30–32; Franchise Agreement §II.A.

The FDD does not disclose a separate franchisor “grand opening authorization” certificate or a mandatory initial-training pass/fail event. The practical readiness gate is therefore the combination of the approved location, executed agreements, legally valid pharmacy operation, required insurance and systems, inventory and staffing, and required pharmacy-network participation—plus any additional state or local conditions applicable to the actual site.

One document point deserves explicit confirmation: Item 16 says the franchisee must sign the MSI InterNet® Participation Agreement, while the FDD table of contents labels Exhibit B as the Medicine Shoppe InterNet® Enrollment Guide. A buyer should obtain and review the current participation agreement that actually governs network terms rather than assuming the enrollment guide is the complete contract.

Sources: 2025 FDD, Items 8, 11, 15 and 16; Franchise Agreement §§II, X and XIV; Exhibit B enrollment materials.

The verified path is a one-location retail-pharmacy franchise process with distinct new-store and conversion timing. The total timeline is officially disclosed as a typical 6–12 months for a new business and 2 weeks–3 months for a conversion, while the separate 12-month and 90-day periods are contractual outside opening limits. The applicant-controlled dependency is getting a viable site, licenses, staffing, systems, insurance, and network onboarding completed; the major external dependencies are Medicap’s site decision and third-party real-estate, regulatory, construction, and network processes.

The most important unresolved point to verify before signing is the exact current application/approval criteria and the complete MSI InterNet participation contract. Also confirm which date Medicap treats as the “grant of the License” for the opening-deadline clock in the buyer’s specific transaction, because the agreement makes failure to commence operations within the applicable period a termination trigger.